Interferon News and Research

RSS

BU researchers find how SARS-CoV-2 infection may drive deadly lung inflammation

Responding to the COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2, requires models that can duplicate disease development in humans, identify potential targets and enable drug testing.

21 Sep 2020

SARS-CoV-2 infects monocytes and macrophages, without cytopathic effect

A team of researchers from Aix-Marseille Univ, IHU-Méditerranée Infection, Institut Paoli Calmettes and Laboratoire d’Immunologie, Marseille, France, conducted experiments to determine if SARS-CoV-2 can affect the myeloid compartment or infect monocytes and macrophages.

20 Sep 2020

Animal data supports efficacy of baricitinib vs SARS-COV-2

The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

India's whole-virion inactivated SARS-CoV-2 vaccine shows promise

Researchers in India have conducted a preclinical study demonstrating the safety and efficacy of a new candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

13 Sep 2020

Study highlights the importance of considering strain differences when designing therapies

Interferon (IFN) responses are one of the first defenses the body mounts against viral infections, and research has shown that it plays a role controlling viral replication.

11 Sep 2020

Effective, simple, safe self-amplifying RNA vaccines

A recent review paper in the journal Current Opinion in Virology in September 2020 shows how a new generation of RNA vaccines called self-amplifying RNA vaccines are more potent than conventional mRNA vaccines and could hold the key to the global production of cost-effective potent COVID-19 vaccines.

11 Sep 2020

Study sheds light on how interferon-gamma drives response to immunotherapy in melanoma

A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds light on how interferon-gamma (IFN-y), an immune response-stimulating signaling molecule that helps activate immune cells, guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -; immune checkpoint blockade.

10 Sep 2020

Scientists explain how SARS-CoV-2 attacks the brain

Now, a team of scientists at Yale University revealed the changes that happen in the brain caused by SARS-CoV-2, the virus that has caused over 27.86 million people and claimed over 903,000 lives.

10 Sep 2020

Study reveals how B cells react to SARS-CoV-2

In an exciting immunological medRxiv preprint paper, researchers from Germany and Russia analyzed adaptive immune response in severely affected patients with coronavirus disease (COVID-19). They demonstrated a protracted immune reaction characterized by egress of B lymphocytes into the blood.

9 Sep 2020

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Researchers in the United States and Germany have conducted a study demonstrating the preclinical efficacy of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

9 Sep 2020

Scientists explain why men are at higher risk from COVID-19

Published in the journal PLOS Biology, the study aimed to provide a better understanding of the mechanisms that drive the varying responses of the infected individuals among different patient demographics, including sex and age.

9 Sep 2020

'Molecular brake' on the immune system could be potential treatment target for severe COVID-19

Older people and people with underlying medical conditions are at particular risk of severe COVID-19. A group of researchers from Charité - Universitätsmedizin Berlin have discovered one possible reason for this vulnerability.

8 Sep 2020

The T cell responses in COVID-19 recovered individuals

A recent study demonstrates that functional CD4+ and CD8+ T cells specifically targeting the entire proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain active in individuals who have recovered from severe or mild coronavirus disease 2019 (COVID-19). Moreover, the magnitude of T cell response is correlated with the antibody response. The study is published in the journal Nature Immunology.

8 Sep 2020

Personalized determination of genetic factors may improve treatment for polycythaemia vera

Polycythaemia vera is a chronic malignant disease of the haematopoietic system and is treated with interferon-alpha-based drugs, in most cases with long-lasting success. However, in some cases this therapy is unsuccessful for reasons that are not yet understood.

8 Sep 2020

Novel RNA vaccine from Arcturus Therapeutics protects mice against SARS-CoV-2

A new study published on the preprint server bioRxiv in September 2020 reports a novel RNA vaccine platform that shows robust protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice and performs much better than a conventional mRNA vaccine. This could allow single-dose immunization, allowing progress towards global vaccination.

6 Sep 2020

Seasonal influenza and COVID-19 risk

In a new study published on the preprint server medRxiv, researchers from Laval University and McGill University in Canada reviewed evidence from 18 relevant studies on a possible interaction between influenza vaccines on non-influenza respiratory disease (NIRD).

6 Sep 2020

Research compares T cell responses to SARS-CoV-2 and influenza

As the COVID-19 pandemic continues to grow, scientists are focusing on understanding how the host immune system responds to the virus in order to better shape public health responses and develop effective vaccines. A new study published on the preprint server medRxiv in September 2020 reports the T cell memory response to the SARS-CoV-2 spike protein, recombinant nucleocapsid protein, and other pooled peptides derived from convalescent patients.

3 Sep 2020

Study identifies subtypes and developmental process of novel immune T cells

There are memory cells that remember previously encountered pathogens and help to react quickly and strongly when exposed to them again.

2 Sep 2020

Scientists solve structure of ORF8 coronavirus protein

Researchers at the University of California and the Lawrence Berkeley National Laboratory have made important discoveries about a protein found on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could lay the foundations for the development of new treatments.

31 Aug 2020